Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy
A phase 2 trial of Exemestane and Fulvestrant in advanced solid tumours, run by CSPC ZhongQi Pharmaceutical Technology Co., Ltd., active and no longer recruiting.
Overview
Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy is a phase 2 interventional study registered as NCT06957379 by CSPC ZhongQi Pharmaceutical Technology Co., Ltd., with 78 participants enrolled, started 2024-02-29 and due to reach its primary completion in 2025-06. Interventions recorded: Letrozole, Anastrozole, Exemestane, Fulvestrant and Sirolimus for Injection (Albumin-bound).
Similar pages
not linked directly; found by shared links- TrialClinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SYS6045 in Patients With HER2-Positive, Expressing, or Mutated Advanced Malignant Solid Tumors
Shares CSPC Pharmaceutical Group, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPhase 1/II Clinical Study of SYS6043 in the Treatment of Advanced/Metastatic Solid Tumors
Shares CSPC Pharmaceutical Group, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialStudy of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)
Shares Exemestane, Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPhase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
Shares Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPhase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Shares Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialSNV4818 in Participants With Advanced Solid Tumors
Shares Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialEvaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Shares Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialOP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
Shares Exemestane, Fulvestrant and the tag pipeline.